Top 10 Reasons to Attend BioProcess International 2015 This Fall

BioProcess International Conference & Exposition is the largest bioprocessing event bringing you new ideas, demystifying technology, and fostering partnerships in highly engaging formats to move drug candidates closer to approval. Register today to attend this year’s meeting, held October 26-29, 2015 at the Hynes Convention Center in Boston, MA.

At the conference, formal and informal networking experiences will connect you to peers, prospects, and customers; parallel tracks give you the option to dive deep or take a big picture approach to learn about industry trends, challenges, and benchmark against the latest research developments and; big pharma and large, mid-size and emerging biotechs collaborating with solution providers will feature proven and next generation technologies – making BPI a one-of-a-kind meeting place.

Above all, here are the top 10 reasons we think BPI is the right bioprocessing event for you:

1.       More than 150+ comprehensive solution providers, next generation technologies, and start-ups – all in one place inside the exposition hall.

2.       6 tracks for one fee. Go specialized or expand your horizons across disciplines for a personalized, curated content experience.

3.       Back by Popular Demand! BPI Theater, a curated showcase of the best innovations.

4.       NEW! Town Hall Forums for highly focused industry best practice sharing.

5.       New and Improved! BPI Connect Partnering App to help jump start your next partnership or collaboration.

6.       NEW! Exposition Hall Tour for focused exhibit viewing led by an industry insider.

7.       NEW! Ask the Regulators Open Forum that will answer your critical questions about regulatory expectations.

8.       NEW! 15 Bioprocessing Problem-Solving Moderated Discussions to help you move drug candidates closer to approval.

9.       The Right Partners for You. Form collaborations and alliances with innovators, suppliers, academia and associations to reach new heights of clinical and commercial success

10.   The Most Comprehensive Science. Capitalize on the latest data-driven research and moderated discussions to move towards commercialization and streamlined development and production from upstream to drug product/fill-finish.

Download the brochure for more information about BPI 2015: http://bit.ly/1NBdz3I

As a valued member of our LinkedIn community, you get $100 off the current rate when you register using code XB15171LINK: http://bit.ly/1NBdz3I

We hope to see you in Boston next month!

Best,

The BPI 2015 Team

@IBCUSA

#BPIConf

Futurebiopharma.blogspot.com

Related articles

• Global Single-use Bioprocessing System Market 2015-2019 - Growing Demand for Biopharmaceuticals ...
• Biotechnologist achieves larger and stronger fruits with plant hormone crystals

Share this article with your social network, just click below to share now!

Share |

Increasing the flexibility of fill finish operations with single-use technology

There are many benefits to using single-use technology for the manufacture of biopharmaceuticals. The enabling aspect of the technology that allows closed-system processing has been examined in a previous post. The single-use principle can be applied across the biomanufacturing process with bioreactors, chromatography and cross flow filtration all available in single-use formats.

Single-Use and Fill Finish

The role of single-use in adding flexibility to fill finish operations will be the subject of a presentation given by Chris Smalley, Ph.D., from Merck & Co. at the Bioprocess International 2015 Conference that will be held in Boston in October. Chris’presentation will be part of the ‘Drug Product Manufacturing & Fill-Finish Processing’ track which is new for this year.

In a recent interview, Chris highlighted the fact that single-use technologies can play an important role in helping to rapidly establish global networks of fill finish operations. These are required in order to meet emerging demands (Merck Champions Single-Use ByAddressing Emotion Vs. Science, by Trisha Gladd at Bioprocess Online)

One way of developing such a network will be to utilize existing manufacturing locations and staff. Minimizing the amount of work required to redevelop these existing facilities around the world will be crucial in achieving the level of operational agility that will likely be required. Taking a single-use approach to fill finish will allow this by reducing the need for HVAC, cleanrooms and WFI systems. The affordability of drugs can be improved as the capital costs, labor requirements and time needed to design and build new facilities will be reduced.

Particulates and Extractables

In the article, Smalley addresses two common concerns about single-use technologies that are particularly pertinent during fill finish operations, namely, particulates and extractables. These are especially important issues for fill finish because there are no further processing steps that can remove impurities derived from equipment or consumables at this stage in the process. Smalley believes that the available studies show that there is little or no risk to patients from particulates and he is an advocate of suppliers providing adopting the BPOG guidelines with respect to extractables.

To facilitate the implementation of single-use across the company, Merck have a Single-Use Network (SUN) of advocates that set guidelines and define good practices. Smalley sees standardization as a key success factor for single-use implementation within the industry. He will no doubt be interested in participating in the Town Hall Forum Discussion on single-use technologies with industry organizations such as BPSA, BPOG, PDA, ASME BPE and ASTM.

Have your say

To what extent do you think challenges, such as particulates and extractables, relating to the implementation of single-use technologies can be overcome?

Dr Nick Hutchinson

Join me at #BPIconf

Contact me at nick.hutchinson@parker.com

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.

Share this article with your social network, just click below to share now!

Share |